Knowledge: Journal Articles

Refine Your Knowledge

Leading journal articles from research around the world

For those who want to go straight to the source.  

1. PSILOCYBIN RESEARCH: End of life related depression and anxiety

Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. Malone, et al. Frontiers in Pharmacology. April 2018. 57(4): 354-388, https://doi.org/10.1177/0022167817706884

Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress. Swift, et al. Journalist of Humanistic Psychology. June 2017. 57(5), 488-519, http://dx.doi.org/10.1177/0022167817715966

Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis. Belser, et. al. Journal of Humnistic Psychology. April 2017. 57(4): 354-388, doi: 10.1177/0022167817706884

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. Griffiths, et al. Journal of Psychopharmacology. December 2016. 30: 1181-1197, doi:10.1177/0269881116675513.

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. Ross, et al. Journal of Psychopharmacology. December 2016. 30: 1165-1180, doi:10.1177/026988111667551.

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer. 2011. Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstadt AL, Greer GR. Arch Gen Psychiatry. Jan 2011, 68(1):71-8.

 

2. PSILOCYBIN RESEARCH: Treatment resistant depression

More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression. Lyons, et al. Frontiers in Psychology. October 2018. 9(1721): 1-11, doi: 10.3389/fpsyg.2018.01721

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. Roseman, et al. Frontiers in Pharmacology. January 2018. 8(974): 1-10, doi: 10.3389/fphar.2017.00974.

Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression. Watts, et al. Journal of Humanistic Psychology. June 2017. 57(5): 520-564, https://doi.org/10.1177/0022167817709585.

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. Carhart-Harris, et al. Psychopharmacology. November 2017. 235(2):399-408, https://doi.org/10.1007/s00213-017-4771-x

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. 2017. Carhart-Harris RL, Roseman L, Bolstridge M, Demetriou L, Pannekoek JN, Wall MB, Tanner M, Kaelen M, McGonigle J, Murphy K, Leech R, Curran HV, Nutt DJ. Scientific Reports 7, Article number: 13187 (2017), doi:10.1038/s41598-017-13282-7.

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. 2016. Carhart-Harris RL, Boldstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran VH, Nutt DJ. The Lancet Psychiatry. 17 May 2016.

 

3. PSILOCYBIN RESEARCH: Major Depressive Disorder

Psilocybin-assisted psychotherapy for the treatment of Major Depressive Disorder: Preliminary results from a randomized controlled trial 2019. Alan K. Davis PhD, Darrick G. May MD, Mary Cosimano MSW, Matthew W. Johnson PhD, Frederick S. Barrett PhD, Roland R. Griffiths PhD. Johns Hopkins University School of Medicine, Department of Psychiatry and Behavioral Sciences, Psychedelic Research Unit

4. PSILOCYBIN RESEARCH: Addiction

Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. Bogenschutz, et al. Frontiers in Pharmacology. February 2018. 9(100):1-7, https://doi.org/10.3389/fphar.2018.00100

Classic hallucinogens in the treatment of addictions. 2015. Bogenschutz MP, Johnson MW. Prog Neuro-Psychopharmacol BiolPsychiatry. Mar 2015.

Long-term follow-up of psilocybin-facilitated smoking cessation: Abstinence outcomes and qualitative analysis of participant accounts. 2015. Garcia-Romeu AP, Noorani T, Griffiths RR, Johnson MW. Drug & Alcohol Dependence, Volume 156, e78. DOI.

Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. 2015. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa PC, Strassman RJ. J Psychopharmacol. 29 Mar 2015, (3):289-99. doi: 10.1177/0269881114565144. Epub 2015 Jan 13.

Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction. 2014. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. J Psychopharmacol. 28 Nov 2014, (11):983-92. doi: 10.1177/0269881114548296. Epub 2014 Sep 11.

 

5. PSILOCYBIN RESEARCH: Other diseases

Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients with Obsessive-Compulsive Disorder.2006. Moreno FA, Wiegand CB, Taitano EK, Delgado PL. J Clin Psychiatry. Nov 2006, 67(11):1735-40.

Response of cluster headache to psilocybin and LSD. 2006. Sewell RA, Halpern JH, Pope HG Jr. Neurology. 27 Jun 2006, 66(12):1920-2.

6. PSILOCYBIN RESEARCH:​ Studies in healthy subjects

High dose psilocybin is associated with positive subjective effects in healthy volunteers.Nicholas, et al. Journal of Psychopharmacology. July 2018. 32(7): 770-778, doi: 10.1177/0269881118780713journals.sagepub.com/home/jop.

Survey study of challenging experiences after ingesting psilocybin mushrooms: Demographics and phenomenology. 2010. Carbonaro TM, Barrett FS, Bradstreet MP, Johnson MW, MacLean KA, Jesse R, Griffiths RR. Drug & Alcohol Dependence. Oct 2010. Volume 146, e239 – e240, 2015.

Psilocybin Biases Facial Recognition, Goal-Directed Behavior, and Mood State Toward Positive Relative to Negative Emotions Through Different Serotonergic Subreceptors. 2012. Kometer M, Schmidt A, Bachmann R, Studerus E, Seifritz E, Vollenweider FX. Biological Psychiatry. Volume 72, Issue 11, 1 Dec 2012, Pages 898-906, ISSN 0006-3223.

Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects.2011. Griffiths RR, Johnson MW, Richards, WA, Richards BD, McCann U, Jesse R. Psychopharmacology (Berl). 2011 Dec, 218(4):649-65. Epub 15 Jun 2011.

Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. 2011. MacLean KA, Johnson MW, Griffiths RR. Journal of Psychopharmacology, 25(11), 1453-1461.

Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. 2011. Studerus E, Kometer M, Hasler F, Vollenweider FX. J Psychopharmacol. 25 Nov 2011: 1434-1452, first published on 20 September 2010 doi: 10.1177/0269881110382466

 

MDMA RESEARCH

1. MDMA RESEARCH: Post Traumatic Stress Disorder (PTSD)

2. MDMA RESEARCH: Social Anxiety

3. MDMA RESEARCH: Safety and Reviews

Safety pharmacology of acute MDMA administration in healthy subjects. Vizeli, P, Liechti, ME J Psychopharmacol 31: 576588.   (2017
Close Menu